No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
ACRS240517C11000
- 1.50
- 0.000.00%
15min DelayClose Oct 26 13:48 ET
0.00High0.00Low
0.00Open1.50Pre Close0 Volume7 Open Interest11.00Strike Price0.00Turnover0.00%IV950.42%PremiumMay 17, 2024Expiry Date0.00Intrinsic Value100Multiplier-2DDays to Expiry1.50Time Value100Contract SizeAmericanOptions Type--Delta--Gamma0.79Leverage Ratio--Theta--Rho--Eff Leverage--Vega
Intraday
- 5D
- 1D
News
Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates
Aclaris Therapeutics, Inc. (NASDAQ:ACRS) defied analyst predictions to release its first-quarter results, which were ahead of market expectations. Results clearly exceeded expectations, with a su
Analysts Offer Insights on Healthcare Companies: Tango Therapeutics (TNGX), Aclaris Therapeutics (ACRS) and Immunocore Holdings (IMCR)
Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Q1 2024 Earnings Call Transcript
Express News | Aclaris Therapeutics Shares Fall 5.2% as Q1 Revenue Declines
Earnings Call Summary | Aclaris Therapeutics(ACRS.US) Q1 2024 Earnings Conference
The following is a summary of the Aclaris Therapeutics, Inc. (ACRS) Q1 2024 Earnings Call Transcript:Financial Performance:Aclaris Therapeutics had $161 million in cash, cash equivalents and marketabl
Q1 2024 Aclaris Therapeutics Inc Earnings Call
Comments
$Aclaris Therapeutics(ACRS.US$ Aclaris Therapeutics GAAP EPS of -$0.02 beats by $0.31, revenue of $17.6M beats by $12.55M
Aclaris Therapeutics' high P/S ratio, alongside declining revenue and the industry's predicted 49% annual growth, could be a significant risk for shareholders and potential investors.
Read more